| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530308000 | Glucagon; related peptides | 23 |
| 20090215981 | Glp-1 Pegylated Compounds - The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (β) cell population, or decreasing gastric or intestinal motility. | 08-27-2009 |
| 20090292106 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE - A new method of synthesizing GLP-1 peptide is devised. | 11-26-2009 |
| 20090306338 | Stabilized GLP-1 Analogs - Polypeptide analogs of the invention that include a) a base amino acid sequence at least 80% identical to one of a GLP-1 fragment; and b) amino acid residues attached to the carboxy terminus of the base amino acid sequence, where the analogs have GLP-1-like activity of longer duration than native GLP-1 and/or the GLP-1 receptor has a greater affinity for the analogs than native GLP-1. Other polypeptide analogs of the invention include a) a base amino acid sequence at least 50% identical to a GLP-1 fragment in which the amino acid residue in the base amino acid sequence corresponding to the P′ | 12-10-2009 |
| 20100029903 | Polypeptide Protracting Tags - The invention provides novel compounds comprising a protracting tag linked to therapeutically active compounds. | 02-04-2010 |
| 20100137558 | MONO MODIFIED EXENDIN WITH POLYETHYLENE GLYCOL OR ITS DERIVATIVES AND USES THEREOF - Disclosed herein are exendin singly modified with polyethylene glycole or a derivative thereof, a method for the preparation of the same, and uses thereof. Exendin modified at lysine (27) with polyethylene glycol shows biological activity similar to that of natural exendin, but is improved in half life. In addition, the modification position and the number of PEG or its derivative are restricted so as to minimize the side effects caused by a variety of combinations of such factors. The exendin is useful in the prevention and treatment of diseases caused by the over-secretion of insulin, or diseases caused due to a decrease in plasma glucose level, the inhibition of gastric or intestinal motility, the promotion of satiety, or the inhibition of food intake, especially diabetes, obesity and irritable colon syndrome. | 06-03-2010 |
| 20120149868 | PURIFICATION OF PEPTIDES PREPARED BY SOLID PHASE SYNTHESIS - The invention relates to an effective process for purifying a peptide which has been prepared by solid phase peptide synthesis. Also encompassed by the invention is a kit comprising reagents for said process and the purified peptide obtained by said process. | 06-14-2012 |
| 20120165503 | OXYNTOMODULIN ANALOGS - Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity. | 06-28-2012 |
| 20120208980 | PROCESS FOR SOLUBILIZING GLUCAGON-LIKE PEPTIDE 1 COMPOUNDS - Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution. | 08-16-2012 |
| 20120309936 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS - Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy. | 12-06-2012 |
| 20120322976 | Preparative RP-HPLC Method For Purifying Peptides - A method for separating on a RP-HPLC system a polypeptide of interest from at least one unwanted component is described, wherein at least one of the elution steps is performed at or in close proximity to the pl value of the peptide of interest. | 12-20-2012 |
| 20130030148 | PROCESS FOR THE SYNTHESIS OF (AIB8,35)HGLP-1(7-36)-NH2 - The present invention relates to a process for the large-scale synthesis of (Aib | 01-31-2013 |
| 20130072658 | PROCESS FOR SOLUBILIZING GLUCAGON-LIKE PEPTIDE 1 COMPOUNDS - Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution. | 03-21-2013 |
| 20130123460 | PEPTIDE FOR IMPROVING BIOSTABILITY OF BIOACTIVE SUBSTANCE, AND BIOACTIVE SUBSTANCE HAVING IMPROVED BIOSTABILITY - The present invention aims at providing a peptide fragment capable of improving biostability of a bioactive substance while maintaining the activity of the bioactive substance, and a bioactive substance to which the peptide fragment is added. The present invention relates to a partial peptide of a GA module having 5 to 25 amino acids, including a partial sequence of a GA module (SEQ ID NO: 1) and the amino acid sequence Ile-Asp-Glu-Ile-Leu (SEQ ID NO: 2), and a bioactive complex in which the partial peptide of the GA module is bound to a bioactive substance. The bioactive substance includes GLP-1, GLP-2, GIP, VIP, somatostatin, amylin, ghrelin, derivatives thereof, and the like. | 05-16-2013 |
| 20130123461 | CONTROLLED DRUG RELEASE FROM DENDRIMERS - The invention relates to compositions that comprise dendrimers useful in medical and veterinary applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the dendrimer through a linkage that releases the drug or a prodrug through controlled beta elimination. | 05-16-2013 |
| 20130123462 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS - Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 05-16-2013 |
| 20130324699 | SYNTHESIS OF GLUCAGON-LIKE PEPTIDE - A new method of synthesizing GLP-1 peptide is devised. | 12-05-2013 |
| 20140206836 | NOVEL N- AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF GH-RH - There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH | 07-24-2014 |
| 20140296476 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES - The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release. | 10-02-2014 |
| 20140336356 | PEPTIDE AGONISTS OF GLP-1 ACTIVITY - Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders. | 11-13-2014 |
| 20150051372 | METHOD FOR PURIFYING SOLID-PHASE SYNTHETIC CRUDE LIRAGLUTIDE - The present invention relates to the field of biomedicine, and in particular, to a method for purifying solid-phase synthetic crude liraglutide. The method comprises: dissolving solid-phase synthetic crude liraglutide in an aqueous acetonitrile solution to obtain a crude peptide solution; and obtaining liraglutide with high purity and high yield through four-step HPLC purification. | 02-19-2015 |
| 20150307580 | OXYNTOMODULIN ANALOGS - Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity. | 10-29-2015 |
| 20150368310 | ANALOGS OF GLUCAGON EXHIBITING GIP RECEPTOR ACTIVITY - Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range. | 12-24-2015 |
| 20160376330 | MATING FACTOR ALPHA PRO-PEPTIDE VARIANTS - The present invention is related to Mating Factor α pro-peptide variants useful for the recombinant expression of polypeptides comprising a GLP-1 peptide in yeasts. The invention is also related to DNA sequences, vectors and host cells for use in expressing polypeptides in yeasts. | 12-29-2016 |
